Update of the Mexican College of Rheumatology Guidelines for the Pharmacological Treatment of Rheumatoid Arthritis, 2018. / Actualización de las guías del tratamiento farmacológico de la artritis reumatoide del Colegio Mexicano de Reumatología 2018.

Therapeutic advances in rheumatoid arthritis require periodic review of treatment guidelines. OBJECTIVE: To update the Mexican College of Rheumatology guidelines on the pharmacological treatment of rheumatoid arthritis. METHOD: Board certified rheumatologists from different health institutions and regions of the country participated. Work teams were formed that reviewed the previous guidelines, elaborated new questions, reviewed the literature, and scored the evidence that was presented and discussed in plenary session. The conclusions were presented to infectologists, gynaecologists and patients. Recommendations were based on levels of evidence according to GRADE methodology. RESULTS: Updated recommendations on the use of available medications for rheumatoid arthritis treatment in Mexico up to 2017 are presented. The importance of adequate and sustained control of the disease is emphasized and relevant safety aspects are described. Bioethical conflicts are included, and government action is invited to strengthen correct treatment of the disease. CONCLUSIONS: The updated recommendations of the Mexican College of Rheumatology on the pharmacological treatment of rheumatoid arthritis incorporate the best available information to be used in the Mexican health care system.

Clinical significance of auditive involvement in rheumatoid arthritis: a case-control study.

Introduction. Rheumatoid arthritis (RA) can involve the incudomalleolar or incudostapedial articulations. Objective. To know the punctual prevalence of audiological alterations in patients with RA. Patients and Methods. RA patients and their controls (Cs), were evaluated by Tonal Audiometry (AU); if there were alterations in the air conduction (AC), bone conduction (BC), Logoaudiometry (LG), and Tympanometry (T) were performed. Results. 45 RA patients and 45 Cs were evaluated. RA patients had 40% of bilateral and 17.8% unilateral alteration versus Cs with 22.2% bilateral and 4.4% unilateral alteration versus Cs with 22.2% bilateral and 4.4% unilateral in AC audiometry. In conventional T (CT) As-type curves in patients with RA, there were 22 LE (48.8%) and 26 RE (57.7%) versus Cs, there were16 RE (35.5%) and 20 LE (44.4%). In High-frequency T (HFT): the 3B1G pattern in RA more frequent versus Controls (Cs) in RE (P = .002 and LE (P = .01). There were no differences according to RA activity or RA disease evolution. Conclusions. There is a greater tendency of auditive loss of As curves in CT (rigidity in ossicular chain) and of the 3B1G pattern in HFT in RA.

Existen los fármacos modificadores en la osteoartritis / Do disease modifying drugs exist for osteoarthritis

La osteoartritis es una enfermedad con gran impacto epidemiológico, social y económico en los sistemas de salud. Su tratamiento se ha centrado en disminuir el dolor y la inflamación articular; en los últimos años ha aparecido en el mercado una serie de medicamentos que, en estudios in vitro, muestran mecanismos de acción que podrían tener un efecto modificador de la enfermedad, ya que disminuyen las citocinas proinflamatorias y las metaloproteinasas implicadas en la degradación de la matriz del cartílago y tienen efecto en mecanismos antiapoptóticos del condrocito. Estudios clínicos han mostrado eficacia contra el dolor y en mejoría de la función articular; algunos estudios han demostrado que no hay pérdida del espacio articular evaluado por radiografía convencional con seguimiento longitudinal de los pacientes. Se trata los mecanismos de acción in vitro que tienen estos nuevos fármacos y la evidencia clínica de su utilidad tanto en los síntomas como por su potencial efecto modificador de la historia natural de la osteoartritis (AU)

The osteoarthritis is a disease with high epidemiological, social, and economic impact in health systems. Its treatment has been focused on diminishing pain and inflammation joint; in last year’s there has appeared on the market a series of drugs that, in studies in vitro show mechanisms of action that might have a modifying effect of disease, since they diminish the proinflammatory cytokines and metalloproteinases involved in degradation of cartilage matrix and it have effect in anti-apoptotics mechanisms in chondrocyte. Clinical studies have showed efficacy against pain and improving joint function; some studies have showed that there is not loss of joint space evaluated by conventional x-ray with longitudinal follow-up of patients. We describe new in vitro action mechanisms of these new drugs and the clinical evidence of its efficacy in symptoms and potentially modifying effect of the natural history of osteoarthritis (AU)

[Do disease modifying drugs exist for osteoarthritis]. / Existen los fármacos modificadores en la osteoartritis.

The osteoarthritis is a disease with high epidemiological, social, and economic impact in health systems. Its treatment has been focused on diminishing pain and inflammation joint; in last years there has appeared on the market a series of drugs that, in studies in vitro show mechanisms of action that might have a modifying effect of disease, since they diminish the proinflammatory cytokines and metalloproteinases involved in degradation of cartilage matrix and it have effect in anti-apoptotics mechanisms in chondrocyte. Clinical studies have showed efficacy against pain and improving joint function; some studies have showed that there is not loss of joint space evaluated by conventional x-ray with longitudinal follow-up of patients. We describe new in vitro action mechanisms of theses new drugs and the clinical evidence of its efficacy in symptoms and potentially modifying effect of the natural history of osteoarthritis.